Hepatitis C Drugs A Good Fit For Outcomes-Based Contracts, McClellan Tells Insurers
The former CMS and FDA head suggested at an AHIP conference that performance-based payments could help pave the way for a new “pricing model” for specialty drugs in the U.S.
You may also be interested in...
FDA’s Janet Woodcock said the agency has not been able to overcome budgetary restrictions that hamper previously discussed plans to develop the Sentinel postmarket drug safety surveillance system into a much broader national resource.
Manufacturers and payers will continue to work on innovative pricing arrangements, roundtable panelists said, but they are likely to be less complex and resource intensive than many of the risk-sharing contracts announced to date, particularly in Europe.
Elizabeth Fowler brings combination of Capitol Hill, White House and pharma industry experience to the role of director of the Center for Medicare and Medicaid Innovation.